Literature DB >> 11565678

Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect.

H Yamauchi1, S Yamaki, M Fujii, H Iwaki, S Tanaka.   

Abstract

We present the case of a patient with atrial septal defect and severe pulmonary hypertension with pulmonary artery peak pressure greater than 110 mm Hg. Open lung biopsy was done prior to the corrective operation, and pathological findings in the small pulmonary arteries included "musculoelastosis" and complete occlusion of 70% of these small arteries and arterioles. The atrial septal defect was closed, and long-term oral prostacyclin therapy was initiated. Pulmonary artery peak pressure decreased to 65 mm Hg 2 years after the operation. This case demonstrates that in a patient with 70% complete occlusion of small pulmonary arteries and arterioles resulting from "musculoelastosis," not only is surgical intervention possible but also pulmonary artery pressure decreases in the long term after operation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11565678     DOI: 10.1016/s0003-4975(00)02537-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Device closure of a large atrial septal defect in a patient with severe pulmonary arterial hypertension after 1 year use of an oral endothelin receptor antagonist.

Authors:  In Hyun Jung; Sang Yun Lee; Sook Jin Lee; Joo Young Lee; Nam Jin Park; Dea Sung Ahn; Jae Hoon Jung; Dong Hee Shin; Dal Soo Lim
Journal:  J Cardiovasc Ultrasound       Date:  2013-09-30

2.  Tailored circulatory intervention in adults with pulmonary hypertension due to congenital heart disease.

Authors:  L E Couperus; I R Henkens; M R M Jongbloed; M G Hazekamp; M J Schalij; H W Vliegen
Journal:  Neth Heart J       Date:  2016-04-20       Impact factor: 2.380

Review 3.  Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery.

Authors:  Nathan Brunner; Vinicio A de Jesus Perez; Alice Richter; François Haddad; André Denault; Vanessa Rojas; Ke Yuan; Mark Orcholski; Xiaobo Liao
Journal:  Pulm Circ       Date:  2014-03       Impact factor: 3.017

4.  Transient use of oral bosentan can be an additional option to reduce pulmonary arterial hypertension in a patient with severe pulmonary arterial hypertension associated with atrial septal defect.

Authors:  Yong Kyu Park; Jae-Hyeong Park; Jae Hyeon Yu; Jun Hyung Kim; Jae-Hwan Lee; Si Wan Choi; Jin-Ok Jeong; In-Whan Seong
Journal:  J Cardiovasc Ultrasound       Date:  2011-09-30

5.  Atrial septal defect with borderline pulmonary vascular disease: surgery and long-term oral prostacyclin therapy for recalcitrant pulmonary hypertension.

Authors:  Hitoshi Yamauchi; Shigeo Yamaki; Masahiro Fujii; Yoshiaki Saji; Masami Ochi; Kazuo Shimizu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-04

6.  Stepwise Approach Using Combined Management in Patients with Congenital Heart Disease and Borderline Pulmonary Vascular Disease.

Authors:  Sang-Yun Lee; Soo-Jin Kim; Jae Sung Son; Seong-Ho Kim; Chang-Ha Lee
Journal:  Korean Circ J       Date:  2015-05-08       Impact factor: 3.243

7.  Pushing the envelope: a treat and repair strategy for patients with advanced pulmonary hypertension associated with congenital heart disease.

Authors:  Rebecca Johnson Kameny; Elizabeth Colglazier; Hythem Nawaytou; Phillip Moore; V Mohan Reddy; David Teitel; Jeffrey R Fineman
Journal:  Pulm Circ       Date:  2017-09-01       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.